Comparison 6. Antifibrinolytic agent versus levonorgestrel intrauterine system.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Median difference in PBAC score			Other data	No numeric data
1.1 After 6 months Rx			Other data	No numeric data
2 Percentage difference in PBAC scores			Other data	No numeric data
2.1 After 6 months Rx			Other data	No numeric data
3 Improvement in mean blood loss (PBAC score < 100)	1	42	Risk Ratio (M‐H, Fixed, 95% CI)	0.43 [0.24, 0.77]
4 Quality of life scores	1		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
4.1 Physical domain	1	42	Mean Difference (IV, Fixed, 95% CI)	0.80 [‐0.78, 2.38]
4.2 Psychological domain	1	42	Mean Difference (IV, Fixed, 95% CI)	‐0.40 [‐1.85, 1.05]
4.3 Social domain	1	42	Mean Difference (IV, Fixed, 95% CI)	0.20 [‐1.55, 1.95]
4.4 Environmental domain	1	42	Mean Difference (IV, Fixed, 95% CI)	1.0 [‐0.06, 2.06]
4.5 Environmental domain TR	1	42	Mean Difference (IV, Fixed, 95% CI)	0.80 [‐0.29, 1.89]
5 Adverse events	1		Odds Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Any adverse event	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	0.83 [0.25, 2.80]
5.2 Headache	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	1.67 [0.34, 8.10]
5.3 Bloating	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.4 Nausea	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	7.36 [0.36, 151.91]
5.5 Weight gain	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	2.86 [0.11, 74.31]
5.6 Rash	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	2.86 [0.11, 74.31]
5.7 Spotting	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	0.11 [0.01, 2.30]
5.8 Breast tenderness	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	0.29 [0.01, 7.51]
5.9 Excess hair growth	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	0.29 [0.01, 7.51]
5.10 Depression	1	42	Odds Ratio (M‐H, Fixed, 95% CI)	0.29 [0.01, 7.51]